Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolization

• Published in: Oncotarget Vol. 6; no. 40; pp. 43090 - 43098
• Main Authors: Yang, Zongguo, Zhang, Jianliang, Lu, Yunfei, Xu, Qingnian, Tang, Bozong, Wang, Qiang, Zhang, Wensi, Chen, Shishi, Lu, Lingqing, Chen, Xiaorong
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 15.12.2015
• Subjects: Aspartate Aminotransferases - blood; Carcinoma, Hepatocellular - immunology; Carcinoma, Hepatocellular - mortality; Carcinoma, Hepatocellular - therapy; Chemoembolization, Therapeutic; Clinical Research Paper; Female; Humans; Inflammation; Kaplan-Meier Estimate; Liver Function Tests; Liver Neoplasms - immunology; Liver Neoplasms - mortality; Liver Neoplasms - therapy; Lymphocyte Count; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; systemic immune-inflammation index; aspartate aminotransferase-lymphocyte ratio index; hepatocellular carcinoma; lymphocyte cell; survival
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.5719

It has been suggested that lymphocytes play central roles in host antitumor immune responses and control cancer outcome. We reviewed the clinical parameters of 189 hepatocellular carcinoma (HCC) patients and investigated the prognostic significance of lymphocyte-related scores in HCC patients following transcatheter arterial chemoembolization (TACE). Survival analysis revealed that an elevated aspartate aminotransferase-lymphocyte ratio index (ALRI) > 57 and a systemic immune-inflammation index (SII) > 300 were negatively associated with overall survival in HBV-related HCC (HR = 2.181, P = 0.003 and HR = 2.453, P = 0.003; respectively). Spearman chi-square analysis showed that ALRI had a specificity of 82.4% and that SII index had a sensitivity of 71.9% for HCC overall survival. ALRI and SII had negative predictive values of 74.6% and 80%, respectively for HCC overall survival. Additionally, Barcelona Clinic Liver Cancer (BCLC) stage C patients had significantly higher ALRI and SII scores (both P < 0.0001) and poorer overall survival (HR = 3.618, P < 0.001). Additionally, HCC patients with portal vein tumor thrombosis (PVTT) had higher ALRI and SII scores (P < 0.0001 and P = 0.0059, respectively). In conclusion, as noninvasive, low cost, easily assessable and reproducible parameters, elevated ALRI and SII should be used as negative predictive factors for overall survival in HBV-related HCC in clinical practice.